COMMUNIQUÉS West-GlobeNewswire

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
04/11/2026
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light
04/11/2026
Proposed new identity reflects the Company’s strategic business expansion following its acquisition of LightSolver; change subject to shareholder approval Rehovot, Israel, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CollPlant [...]
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
04/11/2026
Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will [...]
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
04/11/2026
- Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model - Phase 1/2 clinical trial [...]
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
04/11/2026
ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen’s NDA for UGN-103 (next-generation novel mitomycin-based formulation) for [...]
BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
04/11/2026
CARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (" BioVie " or the " Company "), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative [...]
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
04/11/2026
REDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative [...]
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
04/11/2026
Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial [...]
Sutro Biopharma to Participate in Upcoming Investor Conferences
04/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]
Processa Pharmaceuticals Announces Key Leadership Appointments
04/11/2026
VERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for [...]
Phathom Pharmaceuticals to Participate in November Investor Conferences
04/11/2026
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments
04/11/2026
Transaction provides $500,000 upfront of which $30,000 is in cash and the remainder in shares , representing a 9.4% equity stake in REA Holdings, alongside potential worldwide royalties of up to 8% Strategic divestiture [...]
Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
04/11/2026
Late-breaking oral presentation to highlight efficacy data across tumor types and in the ovarian cancer primary analysis population PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV [...]
Noom Names Leading Awe Researcher Dacher Keltner as Advisor, Announces New National Awe Day
04/11/2026
Keltner to make first public appearance as Noom advisor at Eudēmonia Summit on November 8; inaugural National Awe Day on May 18, 2027, will invite Americans to discover wonder through a 15-minute Awe Walk PRINCETON, N.J [...]
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
04/11/2026
-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: [...]
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
04/11/2026
The study is evaluating the combination in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant non-small cell lung cancer BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, [...]
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
04/11/2026
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026 APR-1051 Phase 1 clinical trial [...]
Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing
04/11/2026
The proposed transaction would value SkinJect® at ~$135 million and include financing at closing to support the SKNJCT-005 NDA-enabling study in Gorlin Syndrome patients PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- [...]
Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Pages